Mesoblast Limited vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.16B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is the larger of the two by market cap, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| MESO | SPHD | |
|---|---|---|
Market Cap | $1.81B | $3.16B |
Volume | 240,620 | 1,245,780 |
Sector | Health | — |
52-Week High | $20.96 | $53.55 |
52-Week Low | $13.19 | $46.96 |
Typical Hold Time | 14 Days | 125 Days |
Enterprise Value | $1.89B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
SPHD trades at $48.19, down 0.58% with a bearish technical outlook showing 17 sell signals versus 4 buy signals. The ETF maintains its high-dividend focus with recent payouts of $0.20-$0.21, though financial ratios remain unavailable. Technical indicators show oversold conditions with RSI at 6.33-14.37 levels while moving averages signal continued downward pressure.
The ETF faces headwinds from underperformance concerns versus peers like SCHD, with media highlighting decade-long return disparities. While monthly dividends appeal to income investors, the lack of quality screening in stock selection poses yield trap risks. Current sentiment leans cautious as analysts question the fund's total return potential amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →